Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04929210 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

Name: A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease — clinical trial record (NCT04929210)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: STAR

StatusActive, Not Recruiting

PhasePhase 4

SponsorJanssen Research & Development, LLC

Started2021-08-30

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

Amendment history 1 change detected by DataLookout

2026-08-29

Primary completion pushed: 2026-08-04 → 2027-04-01

Trial Details

NCT Number	NCT04929210
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Arthritis, Psoriatic
Enrollment	411 participants
Start Date	2021-08-30
Primary Completion	2027-04-01 (estimated)
Study Completion	2027-04-13 (estimated)
Updated on ClinicalTrials.gov	2026-08-28